Symbols / ENTX
ENTX Chart
About
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 72.45M |
| Enterprise Value | 64.09M | Income | -10.78M | Sales | 124.00K |
| Book/sh | 0.33 | Cash/sh | 0.19 | Dividend Yield | — |
| Payout | 0.00% | Employees | 20 | IPO | — |
| P/E | — | Forward P/E | -2.87 | PEG | — |
| P/S | 584.31 | P/B | 4.73 | P/C | — |
| EV/EBITDA | -5.94 | EV/Sales | 516.87 | Quick Ratio | 5.46 |
| Current Ratio | 10.83 | Debt/Eq | 1.39 | LT Debt/Eq | — |
| EPS (ttm) | -0.24 | EPS next Y | -0.55 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -53.80% |
| ROE | -99.43% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -87.29% | Profit Margin | 0.00% | Shs Outstand | 45.86M |
| Shs Float | 31.37M | Short Float | 0.26% | Short Ratio | 0.40 |
| Short Interest | — | 52W High | 3.22 | 52W Low | 1.00 |
| Beta | 1.84 | Avg Volume | 200.76K | Volume | 37.28K |
| Target Price | $10.00 | Recom | None | Prev Close | $1.58 |
| Price | $1.58 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.58
Latest analyst target
3. DCF / Fair value
$-4.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.58
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-09 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-10-07 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-12-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-09-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-05-08 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-04-04 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-03-28 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2022-09-06 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2022-07-19 | main | B. Riley Securities | — → Buy | $5 |
| 2021-06-16 | init | B. Riley Securities | — → Buy | $9 |
| 2021-03-22 | init | Aegis Capital | — → Buy | $12 |
- Entera Bio insiders are buying more of their own shares on market - Stock Titan Wed, 11 Feb 2026 08
- Insider Purchase: Director at $ENTX Buys 18,000 Shares - Quiver Quantitative Wed, 11 Feb 2026 08
- Entera Bio Names Geno Germano Independent Board Chairman - The Globe and Mail ue, 10 Feb 2026 08
- What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours - Benzinga hu, 19 Feb 2026 06
- Entera Bio Shares Rise After Open Market Purchase By Board Members - Nasdaq Wed, 11 Feb 2026 15
- ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead - Stocktwits Wed, 11 Feb 2026 08
- Individual investors are Entera Bio Ltd.'s (NASDAQ:ENTX) biggest owners and were rewarded after market cap rose by US$34m last week - Yahoo Finance Sat, 11 Oct 2025 07
- Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth? - simplywall.st Sat, 31 Jan 2026 08
- What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours - Bitget Wed, 18 Feb 2026 14
- Insider Purchase: Director at $[ENTX] Buys 10,000 Shares - Quiver Quantitative Wed, 11 Feb 2026 13
- Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned - Stock Titan Mon, 09 Feb 2026 08
- Individual investors among Entera Bio Ltd.'s (NASDAQ:ENTX) largest shareholders, saw gain in holdings value after stock jumped 39% last week - simplywall.st Sat, 11 Oct 2025 07
- Rare calcium disorder treated with daily shots may get a pill option - Stock Titan Wed, 04 Feb 2026 08
- $ENTX stock is up 16% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
- Entera Bio (NASDAQ: ENTX) secures FDA agreement on BMD primary endpoint for Phase 3 - Stock Titan Fri, 14 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5000 | 7450 | — | Purchase at price 1.49 per share. | RUBIN STEVEN DANIEL | Director | — | 2026-02-12 00:00:00 | D |
| 1 | 20000 | 29800 | — | Purchase at price 1.49 per share. | GERMANO GENO J | Director | — | 2026-02-10 00:00:00 | D |
| 2 | 7500 | 11100 | — | Purchase at price 1.48 per share. | TAITEL HAYA | Director | — | 2026-02-10 00:00:00 | D |
| 3 | 10000 | 12000 | — | Purchase at price 1.20 per share. | RUBIN STEVEN DANIEL | Director | — | 2026-02-09 00:00:00 | D |
| 4 | 18000 | 22320 | — | Purchase at price 1.24 per share. | ELLIS SEAN | Director | — | 2026-02-09 00:00:00 | D |
| 5 | 38294 | — | — | Stock Award(Grant) at price 0.00 per share. | LIEBERMAN GERALD M | Director | — | 2025-12-31 00:00:00 | D |
| 6 | 28721 | — | — | Stock Award(Grant) at price 0.00 per share. | OSTROV GERALD M | Director | — | 2025-12-31 00:00:00 | D |
| 7 | 25371 | — | — | Stock Award(Grant) at price 0.00 per share. | ELLIS SEAN | Director | — | 2025-12-31 00:00:00 | D |
| 8 | 30157 | — | — | Stock Award(Grant) at price 0.00 per share. | MALCA YONATAN | Director | — | 2025-12-31 00:00:00 | D |
| 9 | 26329 | — | — | Stock Award(Grant) at price 0.00 per share. | TAITEL HAYA | Director | — | 2025-12-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -9.54M | -8.84M | -12.95M | -12.16M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.54M | -8.89M | -13.07M | -12.19M |
| ReconciledDepreciation | 46.00K | 56.00K | 64.00K | 53.00K |
| ReconciledCostOfRevenue | 172.00K | 0.00 | 101.00K | 373.00K |
| EBITDA | -9.54M | -8.84M | -12.95M | -12.16M |
| EBIT | -9.59M | -8.89M | -13.02M | -12.22M |
| NetInterestIncome | 58.00K | 31.00K | 83.00K | -29.00K |
| InterestExpense | 29.00K | |||
| NormalizedIncome | -9.54M | -8.89M | -13.07M | -12.19M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.54M | -8.89M | -13.07M | -12.19M |
| TotalExpenses | 9.77M | 8.89M | 13.15M | 12.79M |
| TotalOperatingIncomeAsReported | -9.59M | -8.89M | -13.02M | -12.22M |
| DilutedAverageShares | 37.65M | 29.01M | 28.81M | 26.13M |
| BasicAverageShares | 37.65M | 29.01M | 28.81M | 26.13M |
| DilutedEPS | -0.25 | -0.31 | -0.45 | -0.47 |
| BasicEPS | -0.25 | -0.31 | -0.45 | -0.47 |
| DilutedNIAvailtoComStockholders | -9.54M | -8.89M | -13.07M | -12.19M |
| NetIncomeCommonStockholders | -9.54M | -8.89M | -13.07M | -12.19M |
| NetIncome | -9.54M | -8.89M | -13.07M | -12.19M |
| NetIncomeIncludingNoncontrollingInterests | -9.54M | -8.89M | -13.07M | -12.19M |
| NetIncomeContinuousOperations | -9.54M | -8.89M | -13.07M | -12.19M |
| TaxProvision | 14.00K | 29.00K | 137.00K | -59.00K |
| PretaxIncome | -9.53M | -8.86M | -12.93M | -12.25M |
| NetNonOperatingInterestIncomeExpense | 58.00K | 31.00K | 83.00K | -29.00K |
| TotalOtherFinanceCost | -58.00K | -31.00K | -83.00K | 29.00K |
| InterestExpenseNonOperating | 29.00K | |||
| OperatingIncome | -9.59M | -8.89M | -13.02M | -12.22M |
| OperatingExpense | 9.59M | 8.89M | 13.05M | 12.41M |
| OtherOperatingExpenses | -49.00K | -51.00K | -46.00K | |
| ResearchAndDevelopment | 4.50M | 4.51M | 5.85M | 6.77M |
| SellingGeneralAndAdministration | 5.09M | 4.43M | 7.25M | 5.69M |
| GeneralAndAdministrativeExpense | 5.09M | 4.43M | 7.25M | 5.69M |
| OtherGandA | 5.09M | 4.43M | 7.25M | 5.69M |
| GrossProfit | 9.00K | 0.00 | 33.00K | 198.00K |
| CostOfRevenue | 172.00K | 0.00 | 101.00K | 373.00K |
| TotalRevenue | 181.00K | 0.00 | 134.00K | 571.00K |
| OperatingRevenue | 181.00K | 0.00 | 134.00K | 571.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 38.84M | 35.48M | 28.81M | 28.80M |
| ShareIssued | 38.84M | 35.48M | 28.81M | 28.80M |
| TotalDebt | 272.00K | 390.00K | 91.00K | 302.00K |
| TangibleBookValue | 8.08M | 10.39M | 11.75M | 22.57M |
| InvestedCapital | 8.08M | 10.39M | 11.75M | 22.57M |
| WorkingCapital | 7.80M | 10.17M | 11.51M | 22.17M |
| NetTangibleAssets | 8.08M | 10.39M | 11.75M | 22.57M |
| CapitalLeaseObligations | 272.00K | 390.00K | 91.00K | 302.00K |
| CommonStockEquity | 8.08M | 10.39M | 11.75M | 22.57M |
| TotalCapitalization | 8.08M | 10.39M | 11.75M | 22.57M |
| TotalEquityGrossMinorityInterest | 8.08M | 10.39M | 11.75M | 22.57M |
| StockholdersEquity | 8.08M | 10.39M | 11.75M | 22.57M |
| GainsLossesNotAffectingRetainedEarnings | 41.00K | 41.00K | 41.00K | 41.00K |
| OtherEquityAdjustments | 41.00K | 41.00K | 41.00K | 41.00K |
| RetainedEarnings | -113.93M | -104.39M | -95.50M | -82.43M |
| AdditionalPaidInCapital | 121.97M | 114.73M | 107.21M | 104.95M |
| CapitalStock | 1.00K | 1.00K | 0.00 | 0.00 |
| CommonStock | 1.00K | 1.00K | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.31M | 1.38M | 1.37M | 3.42M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 134.00K | 288.00K | 32.00K | 261.00K |
| EmployeeBenefits | 32.00K | 32.00K | 32.00K | 138.00K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 32.00K | 32.00K | 32.00K | 138.00K |
| LongTermDebtAndCapitalLeaseObligation | 102.00K | 256.00K | 0.00 | 123.00K |
| LongTermCapitalLeaseObligation | 102.00K | 256.00K | 0.00 | 123.00K |
| CurrentLiabilities | 1.18M | 1.09M | 1.34M | 3.16M |
| CurrentDeferredLiabilities | 0.00 | 15.00K | ||
| CurrentDeferredRevenue | 0.00 | 15.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 170.00K | 134.00K | 91.00K | 179.00K |
| CurrentCapitalLeaseObligation | 170.00K | 134.00K | 91.00K | 179.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 339.00K | 374.00K | 300.00K | 455.00K |
| PayablesAndAccruedExpenses | 667.00K | 583.00K | 950.00K | 2.51M |
| CurrentAccruedExpenses | 535.00K | 500.00K | 933.00K | 2.21M |
| Payables | 132.00K | 83.00K | 17.00K | 300.00K |
| TotalTaxPayable | 0.00 | 134.00K | ||
| IncomeTaxPayable | 0.00 | 134.00K | ||
| AccountsPayable | 132.00K | 83.00K | 17.00K | 166.00K |
| TotalAssets | 9.39M | 11.77M | 13.13M | 25.99M |
| TotalNonCurrentAssets | 418.00K | 508.00K | 278.00K | 658.00K |
| OtherNonCurrentAssets | 80.00K | |||
| DefinedPensionBenefit | 6.00K | 6.00K | 6.00K | 46.00K |
| NonCurrentDeferredAssets | 0.00 | 14.00K | 43.00K | 217.00K |
| NonCurrentDeferredTaxesAssets | 0.00 | 14.00K | 43.00K | 217.00K |
| NetPPE | 332.00K | 488.00K | 229.00K | 395.00K |
| GrossPPE | 332.00K | 488.00K | 229.00K | 395.00K |
| OtherProperties | 332.00K | 488.00K | 229.00K | 395.00K |
| CurrentAssets | 8.97M | 11.26M | 12.85M | 25.33M |
| OtherCurrentAssets | 186.00K | 238.00K | 294.00K | 254.00K |
| Receivables | 126.00K | 0.00 | 246.00K | 183.00K |
| AccountsReceivable | 126.00K | 0.00 | 246.00K | 183.00K |
| CashCashEquivalentsAndShortTermInvestments | 8.66M | 11.02M | 12.31M | 24.89M |
| CashAndCashEquivalents | 8.66M | 11.02M | 12.31M | 24.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.82M | -7.33M | -12.55M | -9.08M |
| IssuanceOfCapitalStock | 3.96M | 6.62M | 0.00 | 21.80M |
| CapitalExpenditure | -3.00K | -17.00K | -47.00K | -17.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 165.00K | 2.00K | |
| EndCashPosition | 8.74M | 11.09M | 12.38M | 24.96M |
| BeginningCashPosition | 11.09M | 12.38M | 24.96M | 8.66M |
| ChangesInCash | -2.35M | -1.29M | -12.59M | 16.30M |
| FinancingCashFlow | 4.48M | 6.04M | 13.00K | 25.38M |
| CashFlowFromContinuingFinancingActivities | 4.48M | 6.04M | 13.00K | 25.38M |
| NetOtherFinancingCharges | -323.00K | -580.00K | ||
| ProceedsFromStockOptionExercised | 839.00K | 0.00 | 13.00K | 3.58M |
| NetCommonStockIssuance | 3.96M | 6.62M | 0.00 | 21.80M |
| CommonStockIssuance | 3.96M | 6.62M | 0.00 | 21.80M |
| InvestingCashFlow | -3.00K | -17.00K | -102.00K | -17.00K |
| CashFlowFromContinuingInvestingActivities | -3.00K | -17.00K | -102.00K | -17.00K |
| NetOtherInvestingChanges | -55.00K | |||
| NetPPEPurchaseAndSale | -3.00K | -17.00K | -47.00K | -17.00K |
| PurchaseOfPPE | -3.00K | -17.00K | -47.00K | -17.00K |
| OperatingCashFlow | -6.82M | -7.31M | -12.50M | -9.06M |
| CashFlowFromContinuingOperatingActivities | -6.82M | -7.31M | -12.50M | -9.06M |
| ChangeInWorkingCapital | 112.00K | -195.00K | -1.83M | 1.41M |
| ChangeInOtherWorkingCapital | -15.00K | -143.00K | ||
| ChangeInOtherCurrentAssets | -14.00K | 56.00K | -40.00K | 7.00K |
| ChangeInPayablesAndAccruedExpense | 252.00K | -497.00K | -1.72M | 1.47M |
| ChangeInAccruedExpense | 203.00K | -563.00K | -1.57M | 1.47M |
| ChangeInPayable | 49.00K | 66.00K | -149.00K | 2.00K |
| ChangeInAccountPayable | 49.00K | 66.00K | -149.00K | 2.00K |
| ChangeInReceivables | -126.00K | 246.00K | -63.00K | 72.00K |
| ChangesInAccountReceivables | -126.00K | 246.00K | -63.00K | 72.00K |
| OtherNonCashItems | -5.00K | -78.00K | 18.00K | |
| StockBasedCompensation | 2.56M | 1.69M | 2.25M | 1.86M |
| DeferredTax | 14.00K | 29.00K | 174.00K | -217.00K |
| DeferredIncomeTax | 14.00K | 29.00K | 174.00K | -217.00K |
| DepreciationAmortizationDepletion | 46.00K | 56.00K | 64.00K | 53.00K |
| DepreciationAndAmortization | 46.00K | 56.00K | 64.00K | 53.00K |
| Depreciation | 46.00K | 56.00K | 64.00K | 53.00K |
| NetIncomeFromContinuingOperations | -9.54M | -8.89M | -13.07M | -12.19M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ENTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|